chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19, FLU4
Symptoms: Chest pain, Chills, Dyspnoea, Fatigue, Headache
Clinical narrative: 8 hours after the COVID vaccine, patient got a fever, headache, muscle pain, fatigue, chills, body aches. These symptoms lasted for about 48 hours. Then just about 4 days after the COVID vaccine, patient developed chest pains and difficulty breathing. He went to the ER where he was diagnosed with perimyocarditis.
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19, FLU4
Symptoms: Immunodeficiency, Myalgia, Myocarditis, Pain, Pyrexia
Clinical narrative: 8 hours after the COVID vaccine, patient got a fever, headache, muscle pain, fatigue, chills, body aches. These symptoms lasted for about 48 hours. Then just about 4 days after the COVID vaccine, patient developed chest pains and difficulty breathing. He went to the ER where he was diagnosed with perimyocarditis.
Age: 28.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Dyskinesia, Face injury, Fall, Memory impairment
Clinical narrative: Within 10 minutes of receiving the shot, I had a seizure.  I have never had a seizure before in my life.  The seizure caused me to fall off of the bed in the room and hit my head on the floor.    With the help of EMT, I regained awareness 20-30 minutes after the seizure began.  The fall cause me to split my head open near my eyebrow.  I was taken to the emergency room and received several stitches at the wound site.  The emergency room doctor also told me I had a minor concussion.
Age: 28.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Muscle tightness, Musculoskeletal stiffness
Clinical narrative: Within 10 minutes of receiving the shot, I had a seizure.  I have never had a seizure before in my life.  The seizure caused me to fall off of the bed in the room and hit my head on the floor.    With the help of EMT, I regained awareness 20-30 minutes after the seizure began.  The fall cause me to split my head open near my eyebrow.  I was taken to the emergency room and received several stitches at the wound site.  The emergency room doctor also told me I had a minor concussion.
Age: 28.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood potassium decreased, Computerised tomogram normal, Concussion, Fall, Head injury
Clinical narrative: Within 10 minutes of receiving the shot, I had a seizure.  I have never had a seizure before in my life.  The seizure caused me to fall off of the bed in the room and hit my head on the floor.    With the help of EMT, I regained awareness 20-30 minutes after the seizure began.  The fall cause me to split my head open near my eyebrow.  I was taken to the emergency room and received several stitches at the wound site.  The emergency room doctor also told me I had a minor concussion.
Age: 28.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Seizure, Unresponsive to stimuli
Clinical narrative: Within 10 minutes of receiving the shot, I had a seizure.  I have never had a seizure before in my life.  The seizure caused me to fall off of the bed in the room and hit my head on the floor.    With the help of EMT, I regained awareness 20-30 minutes after the seizure began.  The fall cause me to split my head open near my eyebrow.  I was taken to the emergency room and received several stitches at the wound site.  The emergency room doctor also told me I had a minor concussion.
Age: 24.0
Sex: F
Vaccine: COVID19, UNK, COVID19, COVID19
Symptoms: Blood test, Seizure
Clinical narrative: 3 back to back seizures; patient was pregnant; This is a spontaneous report from a contactable consumer (patient). A 24-year-old female patient received the second dose of BNT162B2 (PFIZER COVID-19 VACCINE, Lot Number: 301558A), at the age of 24 years old, via an unspecified route of administration in left arm on 19Oct2021 at 09:45 at single dose for COVID-19 immunisation. The patient's medical history was not reported. The patient was not diagnosed with COVID-19 prior vaccination. The patient was pregnant at time of vaccination. Last menstrual date was 19Jul2021. The patient was due to deliver on 02Apr2022. Gestational period at exposure was 13 weeks. The patient did not receive other vaccine in four weeks. Concomitant medication in two weeks included ascorbic acid/beta carotene/calcium carbonate/colecalciferol/cyanocobalamin/dl-alpha tocopheryl acetate/ferrous fumarate/folic acid/nicotinamide/pyridoxine hydrochloride/riboflavin/thiamine mononitrate/zinc oxide (PRENATAL). The patient previously took amoxicillin, cefuroxime axetil (CEFTIN), ceftriaxone sodium/tazobactam sodium (BACTRUM T, reported as BACTRUM), nitrofurantoin (MACRODANTIN) and all experienced known allergies. The patient previously received the first dose of BNT162B2 (Lot Number: FE3592), at the age of 24 years old, in left arm on 28Sep2021 at 11:00 at single dose for COVID-19 immunisation and experienced maternal exposure during pregnancy. The patient experienced 3 back to back seizures on 19Oct2021 at 09:45. Event seizures resulted in emergency room (ER)/department or urgent care. The patient was not tested for COVID-19 post vaccination. Therapeutic measures were taken as a result of event seizures and included treatment with ER visit and workup. Outcome of event seizures was recovering. Outcome of event patient was pregnant was unknown.
Age: 24.0
Sex: F
Vaccine: COVID19, UNK, COVID19, COVID19
Symptoms: Maternal exposure during pregnancy, Seizure
Clinical narrative: 3 back to back seizures; patient was pregnant; This is a spontaneous report from a contactable consumer (patient). A 24-year-old female patient received the second dose of BNT162B2 (PFIZER COVID-19 VACCINE, Lot Number: 301558A), at the age of 24 years old, via an unspecified route of administration in left arm on 19Oct2021 at 09:45 at single dose for COVID-19 immunisation. The patient's medical history was not reported. The patient was not diagnosed with COVID-19 prior vaccination. The patient was pregnant at time of vaccination. Last menstrual date was 19Jul2021. The patient was due to deliver on 02Apr2022. Gestational period at exposure was 13 weeks. The patient did not receive other vaccine in four weeks. Concomitant medication in two weeks included ascorbic acid/beta carotene/calcium carbonate/colecalciferol/cyanocobalamin/dl-alpha tocopheryl acetate/ferrous fumarate/folic acid/nicotinamide/pyridoxine hydrochloride/riboflavin/thiamine mononitrate/zinc oxide (PRENATAL). The patient previously took amoxicillin, cefuroxime axetil (CEFTIN), ceftriaxone sodium/tazobactam sodium (BACTRUM T, reported as BACTRUM), nitrofurantoin (MACRODANTIN) and all experienced known allergies. The patient previously received the first dose of BNT162B2 (Lot Number: FE3592), at the age of 24 years old, in left arm on 28Sep2021 at 11:00 at single dose for COVID-19 immunisation and experienced maternal exposure during pregnancy. The patient experienced 3 back to back seizures on 19Oct2021 at 09:45. Event seizures resulted in emergency room (ER)/department or urgent care. The patient was not tested for COVID-19 post vaccination. Therapeutic measures were taken as a result of event seizures and included treatment with ER visit and workup. Outcome of event seizures was recovering. Outcome of event patient was pregnant was unknown.
Age: 24.0
Sex: F
Vaccine: COVID19, UNK, COVID19, COVID19
Symptoms: Blood test, Dizziness, Drooling, Electrocardiogram, Exposure during pregnancy
Clinical narrative: 3 back to back seizures; patient was pregnant; This is a spontaneous report from a contactable consumer (patient). A 24-year-old female patient received the second dose of BNT162B2 (PFIZER COVID-19 VACCINE, Lot Number: 301558A), at the age of 24 years old, via an unspecified route of administration in left arm on 19Oct2021 at 09:45 at single dose for COVID-19 immunisation. The patient's medical history was not reported. The patient was not diagnosed with COVID-19 prior vaccination. The patient was pregnant at time of vaccination. Last menstrual date was 19Jul2021. The patient was due to deliver on 02Apr2022. Gestational period at exposure was 13 weeks. The patient did not receive other vaccine in four weeks. Concomitant medication in two weeks included ascorbic acid/beta carotene/calcium carbonate/colecalciferol/cyanocobalamin/dl-alpha tocopheryl acetate/ferrous fumarate/folic acid/nicotinamide/pyridoxine hydrochloride/riboflavin/thiamine mononitrate/zinc oxide (PRENATAL). The patient previously took amoxicillin, cefuroxime axetil (CEFTIN), ceftriaxone sodium/tazobactam sodium (BACTRUM T, reported as BACTRUM), nitrofurantoin (MACRODANTIN) and all experienced known allergies. The patient previously received the first dose of BNT162B2 (Lot Number: FE3592), at the age of 24 years old, in left arm on 28Sep2021 at 11:00 at single dose for COVID-19 immunisation and experienced maternal exposure during pregnancy. The patient experienced 3 back to back seizures on 19Oct2021 at 09:45. Event seizures resulted in emergency room (ER)/department or urgent care. The patient was not tested for COVID-19 post vaccination. Therapeutic measures were taken as a result of event seizures and included treatment with ER visit and workup. Outcome of event seizures was recovering. Outcome of event patient was pregnant was unknown.
Age: 24.0
Sex: F
Vaccine: COVID19, UNK, COVID19, COVID19
Symptoms: Seizure like phenomena, Unresponsive to stimuli, Vomiting
Clinical narrative: 3 back to back seizures; patient was pregnant; This is a spontaneous report from a contactable consumer (patient). A 24-year-old female patient received the second dose of BNT162B2 (PFIZER COVID-19 VACCINE, Lot Number: 301558A), at the age of 24 years old, via an unspecified route of administration in left arm on 19Oct2021 at 09:45 at single dose for COVID-19 immunisation. The patient's medical history was not reported. The patient was not diagnosed with COVID-19 prior vaccination. The patient was pregnant at time of vaccination. Last menstrual date was 19Jul2021. The patient was due to deliver on 02Apr2022. Gestational period at exposure was 13 weeks. The patient did not receive other vaccine in four weeks. Concomitant medication in two weeks included ascorbic acid/beta carotene/calcium carbonate/colecalciferol/cyanocobalamin/dl-alpha tocopheryl acetate/ferrous fumarate/folic acid/nicotinamide/pyridoxine hydrochloride/riboflavin/thiamine mononitrate/zinc oxide (PRENATAL). The patient previously took amoxicillin, cefuroxime axetil (CEFTIN), ceftriaxone sodium/tazobactam sodium (BACTRUM T, reported as BACTRUM), nitrofurantoin (MACRODANTIN) and all experienced known allergies. The patient previously received the first dose of BNT162B2 (Lot Number: FE3592), at the age of 24 years old, in left arm on 28Sep2021 at 11:00 at single dose for COVID-19 immunisation and experienced maternal exposure during pregnancy. The patient experienced 3 back to back seizures on 19Oct2021 at 09:45. Event seizures resulted in emergency room (ER)/department or urgent care. The patient was not tested for COVID-19 post vaccination. Therapeutic measures were taken as a result of event seizures and included treatment with ER visit and workup. Outcome of event seizures was recovering. Outcome of event patient was pregnant was unknown.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Angiogram, Injection site hypoaesthesia, Injection site pain, Pain in extremity, Scan with contrast
Clinical narrative: more pain and numbness in his left arm, chest, hand/fingers; more pain and numbness in his left arm, chest, hand/fingers; a blood clot in his left ring finger/possibly thrombosis; nausea; pain and numbness at the injection site (left arm)/pain lasting longer, and more frequently; pain and numbness at the injection site (left arm)/more pain and numbness in his left arm, chest, hand/fingers; vomiting; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EL9265), via an unspecified route of administration, administered in left arm on 03Feb2021 08:30 AM (at 49-year-old) as dose 2, single for COVID-19 immunization. Medical history included known allergies: penicillin. There were no concomitant medications. No other vaccine in four weeks. On other medications in two weeks. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: EK9231), via an unspecified route of administration, administered in left arm on 13Jan2021 08:30 AM (at 49-year-old) as dose 1, single for Covid-19 Immunization. The day of the patient's first shot, he experienced nausea, pain and numbness at the injection site (left arm), and vomiting. It subsided a few days later. After his second dose, he experienced the same discomfort; with the exception of symptoms and pain lasting longer, and more frequently in 2021. In Aug2021, he began experiencing more pain and numbness in his left arm, chest, hand/fingers. In Oct2021, the pain became unbearable, so he went to the emergency room at which time an MRI was administered. Patient was informed he had a blood clot in his left ring finger, and possibly thrombosis. He had since been prescribed blood thinner, pain medications, and a referral to a hand and a blood specialist. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, life threatening illness (immediate risk of death from the event), disability or permanent damage. The patient underwent lab tests and procedures which included magnetic resonance imaging (MRI): unknown results in Oct2021, Rapid Test QuickVue: negative on 01Sep2021 (Nasal Swab), x-ray: unknown results on an unspecified date. The treatment for the events was reported as MRI X-ray, medications, follow-up, referrals. The outcome of the events was not recovered.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Thrombosis
Clinical narrative: more pain and numbness in his left arm, chest, hand/fingers; more pain and numbness in his left arm, chest, hand/fingers; a blood clot in his left ring finger/possibly thrombosis; nausea; pain and numbness at the injection site (left arm)/pain lasting longer, and more frequently; pain and numbness at the injection site (left arm)/more pain and numbness in his left arm, chest, hand/fingers; vomiting; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EL9265), via an unspecified route of administration, administered in left arm on 03Feb2021 08:30 AM (at 49-year-old) as dose 2, single for COVID-19 immunization. Medical history included known allergies: penicillin. There were no concomitant medications. No other vaccine in four weeks. On other medications in two weeks. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: EK9231), via an unspecified route of administration, administered in left arm on 13Jan2021 08:30 AM (at 49-year-old) as dose 1, single for Covid-19 Immunization. The day of the patient's first shot, he experienced nausea, pain and numbness at the injection site (left arm), and vomiting. It subsided a few days later. After his second dose, he experienced the same discomfort; with the exception of symptoms and pain lasting longer, and more frequently in 2021. In Aug2021, he began experiencing more pain and numbness in his left arm, chest, hand/fingers. In Oct2021, the pain became unbearable, so he went to the emergency room at which time an MRI was administered. Patient was informed he had a blood clot in his left ring finger, and possibly thrombosis. He had since been prescribed blood thinner, pain medications, and a referral to a hand and a blood specialist. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, life threatening illness (immediate risk of death from the event), disability or permanent damage. The patient underwent lab tests and procedures which included magnetic resonance imaging (MRI): unknown results in Oct2021, Rapid Test QuickVue: negative on 01Sep2021 (Nasal Swab), x-ray: unknown results on an unspecified date. The treatment for the events was reported as MRI X-ray, medications, follow-up, referrals. The outcome of the events was not recovered.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chest pain, Hypoaesthesia, Magnetic resonance imaging, Nausea, Pain in extremity
Clinical narrative: more pain and numbness in his left arm, chest, hand/fingers; more pain and numbness in his left arm, chest, hand/fingers; a blood clot in his left ring finger/possibly thrombosis; nausea; pain and numbness at the injection site (left arm)/pain lasting longer, and more frequently; pain and numbness at the injection site (left arm)/more pain and numbness in his left arm, chest, hand/fingers; vomiting; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EL9265), via an unspecified route of administration, administered in left arm on 03Feb2021 08:30 AM (at 49-year-old) as dose 2, single for COVID-19 immunization. Medical history included known allergies: penicillin. There were no concomitant medications. No other vaccine in four weeks. On other medications in two weeks. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: EK9231), via an unspecified route of administration, administered in left arm on 13Jan2021 08:30 AM (at 49-year-old) as dose 1, single for Covid-19 Immunization. The day of the patient's first shot, he experienced nausea, pain and numbness at the injection site (left arm), and vomiting. It subsided a few days later. After his second dose, he experienced the same discomfort; with the exception of symptoms and pain lasting longer, and more frequently in 2021. In Aug2021, he began experiencing more pain and numbness in his left arm, chest, hand/fingers. In Oct2021, the pain became unbearable, so he went to the emergency room at which time an MRI was administered. Patient was informed he had a blood clot in his left ring finger, and possibly thrombosis. He had since been prescribed blood thinner, pain medications, and a referral to a hand and a blood specialist. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, life threatening illness (immediate risk of death from the event), disability or permanent damage. The patient underwent lab tests and procedures which included magnetic resonance imaging (MRI): unknown results in Oct2021, Rapid Test QuickVue: negative on 01Sep2021 (Nasal Swab), x-ray: unknown results on an unspecified date. The treatment for the events was reported as MRI X-ray, medications, follow-up, referrals. The outcome of the events was not recovered.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: SARS-CoV-2 test, Thrombosis, Vaccination site pain, Vomiting, X-ray
Clinical narrative: more pain and numbness in his left arm, chest, hand/fingers; more pain and numbness in his left arm, chest, hand/fingers; a blood clot in his left ring finger/possibly thrombosis; nausea; pain and numbness at the injection site (left arm)/pain lasting longer, and more frequently; pain and numbness at the injection site (left arm)/more pain and numbness in his left arm, chest, hand/fingers; vomiting; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EL9265), via an unspecified route of administration, administered in left arm on 03Feb2021 08:30 AM (at 49-year-old) as dose 2, single for COVID-19 immunization. Medical history included known allergies: penicillin. There were no concomitant medications. No other vaccine in four weeks. On other medications in two weeks. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: EK9231), via an unspecified route of administration, administered in left arm on 13Jan2021 08:30 AM (at 49-year-old) as dose 1, single for Covid-19 Immunization. The day of the patient's first shot, he experienced nausea, pain and numbness at the injection site (left arm), and vomiting. It subsided a few days later. After his second dose, he experienced the same discomfort; with the exception of symptoms and pain lasting longer, and more frequently in 2021. In Aug2021, he began experiencing more pain and numbness in his left arm, chest, hand/fingers. In Oct2021, the pain became unbearable, so he went to the emergency room at which time an MRI was administered. Patient was informed he had a blood clot in his left ring finger, and possibly thrombosis. He had since been prescribed blood thinner, pain medications, and a referral to a hand and a blood specialist. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, life threatening illness (immediate risk of death from the event), disability or permanent damage. The patient underwent lab tests and procedures which included magnetic resonance imaging (MRI): unknown results in Oct2021, Rapid Test QuickVue: negative on 01Sep2021 (Nasal Swab), x-ray: unknown results on an unspecified date. The treatment for the events was reported as MRI X-ray, medications, follow-up, referrals. The outcome of the events was not recovered.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Arthropathy, Disturbance in attention, Dizziness, Emotional disorder
Clinical narrative: cant move all of his joints; cant move all of his muscles; lightheadedness; insomnia; joints are hurting unbelievably bad; muscles are hurting unbelievably bad; Headache; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 14Apr2021 (71-year-old at the time of vaccination) as dose 2, single for covid-19 immunization. The patients medical history and concomitant medications were not reported. Historical vaccine includes first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date (71-year-old at the time of vaccination) as dose 1, single for COVID-19 immunization. On an unspecified date, the patient experienced cannot move all of his joints, cannot move all of his muscles, joints are hurting unbelievably bad, muscles are hurting unbelievably bad, lightheadedness, headache and insomnia. The patient stated he could not move all of his muscles and joints and they were hurting unbelievably bad. The patient stated he could not put his legs on the bed. The patient wanted to know if there was anything he can do to relieve the pain. The patient wanted to know if his side effects would be permanent. The patient wanted to know how long the side effects would last. The patient also stated he had lightheadedness, headaches and insomnia. The outcome of the events was unknown. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Headache, Hypokinesia, Insomnia, Ligament disorder
Clinical narrative: cant move all of his joints; cant move all of his muscles; lightheadedness; insomnia; joints are hurting unbelievably bad; muscles are hurting unbelievably bad; Headache; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 14Apr2021 (71-year-old at the time of vaccination) as dose 2, single for covid-19 immunization. The patients medical history and concomitant medications were not reported. Historical vaccine includes first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date (71-year-old at the time of vaccination) as dose 1, single for COVID-19 immunization. On an unspecified date, the patient experienced cannot move all of his joints, cannot move all of his muscles, joints are hurting unbelievably bad, muscles are hurting unbelievably bad, lightheadedness, headache and insomnia. The patient stated he could not move all of his muscles and joints and they were hurting unbelievably bad. The patient stated he could not put his legs on the bed. The patient wanted to know if there was anything he can do to relieve the pain. The patient wanted to know if his side effects would be permanent. The patient wanted to know how long the side effects would last. The patient also stated he had lightheadedness, headaches and insomnia. The outcome of the events was unknown. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Ligament pain, Muscle disorder, Myalgia, Pelvic pain
Clinical narrative: cant move all of his joints; cant move all of his muscles; lightheadedness; insomnia; joints are hurting unbelievably bad; muscles are hurting unbelievably bad; Headache; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 14Apr2021 (71-year-old at the time of vaccination) as dose 2, single for covid-19 immunization. The patients medical history and concomitant medications were not reported. Historical vaccine includes first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date (71-year-old at the time of vaccination) as dose 1, single for COVID-19 immunization. On an unspecified date, the patient experienced cannot move all of his joints, cannot move all of his muscles, joints are hurting unbelievably bad, muscles are hurting unbelievably bad, lightheadedness, headache and insomnia. The patient stated he could not move all of his muscles and joints and they were hurting unbelievably bad. The patient stated he could not put his legs on the bed. The patient wanted to know if there was anything he can do to relieve the pain. The patient wanted to know if his side effects would be permanent. The patient wanted to know how long the side effects would last. The patient also stated he had lightheadedness, headaches and insomnia. The outcome of the events was unknown. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Dizziness, Headache, Insomnia, Joint stiffness
Clinical narrative: cant move all of his joints; cant move all of his muscles; lightheadedness; insomnia; joints are hurting unbelievably bad; muscles are hurting unbelievably bad; Headache; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 14Apr2021 (71-year-old at the time of vaccination) as dose 2, single for covid-19 immunization. The patients medical history and concomitant medications were not reported. Historical vaccine includes first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date (71-year-old at the time of vaccination) as dose 1, single for COVID-19 immunization. On an unspecified date, the patient experienced cannot move all of his joints, cannot move all of his muscles, joints are hurting unbelievably bad, muscles are hurting unbelievably bad, lightheadedness, headache and insomnia. The patient stated he could not move all of his muscles and joints and they were hurting unbelievably bad. The patient stated he could not put his legs on the bed. The patient wanted to know if there was anything he can do to relieve the pain. The patient wanted to know if his side effects would be permanent. The patient wanted to know how long the side effects would last. The patient also stated he had lightheadedness, headaches and insomnia. The outcome of the events was unknown. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Musculoskeletal stiffness, Myalgia
Clinical narrative: cant move all of his joints; cant move all of his muscles; lightheadedness; insomnia; joints are hurting unbelievably bad; muscles are hurting unbelievably bad; Headache; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 14Apr2021 (71-year-old at the time of vaccination) as dose 2, single for covid-19 immunization. The patients medical history and concomitant medications were not reported. Historical vaccine includes first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 Vaccine, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date (71-year-old at the time of vaccination) as dose 1, single for COVID-19 immunization. On an unspecified date, the patient experienced cannot move all of his joints, cannot move all of his muscles, joints are hurting unbelievably bad, muscles are hurting unbelievably bad, lightheadedness, headache and insomnia. The patient stated he could not move all of his muscles and joints and they were hurting unbelievably bad. The patient stated he could not put his legs on the bed. The patient wanted to know if there was anything he can do to relieve the pain. The patient wanted to know if his side effects would be permanent. The patient wanted to know how long the side effects would last. The patient also stated he had lightheadedness, headaches and insomnia. The outcome of the events was unknown. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pruritus, Rash, Scar, Scratch
Clinical narrative: broken out in terrible rash up and down back; itching is relentless; could not sleep; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 60-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Formulation: Solution for injection Lot number was not reported) via an unspecified route of administration on 08Apr2021 (at the age of 60-year-old) as DOSE 2, SINGLE for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Historical vaccine includes BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Formulation: Solution for injection Lot number was not reported) via an unspecified route of administration on an unspecified date (at the age of 60-year-old) as DOSE 1, SINGLE for COVID-19 immunization. The second dose was received on 08Apr2021, later that night she broke out in a terrible rash up and down back neck to butt. The itching is relentless, patient could not sleep at night because of the issue. She saw her primary care doctor who prescribed her an ointment but its not an ointment. Outcome of events was unknown. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Insomnia, Pruritus, Rash
Clinical narrative: broken out in terrible rash up and down back; itching is relentless; could not sleep; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 60-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Formulation: Solution for injection Lot number was not reported) via an unspecified route of administration on 08Apr2021 (at the age of 60-year-old) as DOSE 2, SINGLE for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Historical vaccine includes BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Formulation: Solution for injection Lot number was not reported) via an unspecified route of administration on an unspecified date (at the age of 60-year-old) as DOSE 1, SINGLE for COVID-19 immunization. The second dose was received on 08Apr2021, later that night she broke out in a terrible rash up and down back neck to butt. The itching is relentless, patient could not sleep at night because of the issue. She saw her primary care doctor who prescribed her an ointment but its not an ointment. Outcome of events was unknown. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity
Clinical narrative: she had a little bit of soreness in right arm after she received the COVID-19 Vaccine; This is a spontaneous report from a contactable consumer (Patient). A 42-years-old female patient received first dose of BNT162B2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: EM9809), via an unspecified route of administration, administered in right arm on 24Feb2021 at 09:30 (at the age of 42-year-old) as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient family history included her grandmother died from the COVID-19 Virus. On 24Feb2021, the patient experienced she had a little bit of soreness in right arm after she received the COVID-19 Vaccine. The patient did not received treatment. The clinical outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccination site pain
Clinical narrative: she had a little bit of soreness in right arm after she received the COVID-19 Vaccine; This is a spontaneous report from a contactable consumer (Patient). A 42-years-old female patient received first dose of BNT162B2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: EM9809), via an unspecified route of administration, administered in right arm on 24Feb2021 at 09:30 (at the age of 42-year-old) as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient family history included her grandmother died from the COVID-19 Virus. On 24Feb2021, the patient experienced she had a little bit of soreness in right arm after she received the COVID-19 Vaccine. The patient did not received treatment. The clinical outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
Age: 43.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product storage error
Clinical narrative: The patient was given an expired Johnson and Johnson vaccine. It was 4 days after the expiration date.  The patient has not had any adverse reactions since receiving the vaccine.
Age: 43.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: The patient was given an expired Johnson and Johnson vaccine. It was 4 days after the expiration date.  The patient has not had any adverse reactions since receiving the vaccine.
Age: 57.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Hemianaesthesia, Hemiparaesthesia
Clinical narrative: Numbness and prickling sensation on entire left side of body, arm, hand, fingers, leg, foot, and toes started on Day 2 post vaccination of Moderna Booster. On Day 4 went to emergency room as numbness and prickling sensation continued over entire left side of body, arm, hand, fingers, leg, foot, and toes and radiated to left side of face.   Numbness and prickliness lasted approximately 1-5 minutes over 4 days.   Treatment:  Rest and monitor   Diagnosis:  Parethesia
Age: 57.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Computerised tomogram head, Hypoaesthesia, Laboratory test, Paraesthesia, Sensory disturbance
Clinical narrative: Numbness and prickling sensation on entire left side of body, arm, hand, fingers, leg, foot, and toes started on Day 2 post vaccination of Moderna Booster. On Day 4 went to emergency room as numbness and prickling sensation continued over entire left side of body, arm, hand, fingers, leg, foot, and toes and radiated to left side of face.   Numbness and prickliness lasted approximately 1-5 minutes over 4 days.   Treatment:  Rest and monitor   Diagnosis:  Parethesia
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Feeling hot, Hypoaesthesia, Pruritus, Tenderness
Clinical narrative: pt states like the injection felt like it very deep almost to the bone.  Her left arm was sore, swollen, hot and had red splotches on it.  These symptoms lasted for about a week before they gradually went away.  She still has a hard spot around the injection site that she can still feel.  She no longer has any pain from this.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Feeling hot, Injection site induration, Pain in extremity, Peripheral swelling, Rash macular
Clinical narrative: pt states like the injection felt like it very deep almost to the bone.  Her left arm was sore, swollen, hot and had red splotches on it.  These symptoms lasted for about a week before they gradually went away.  She still has a hard spot around the injection site that she can still feel.  She no longer has any pain from this.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Blood test, Epistaxis
Clinical narrative: nosebleed, hesitating to take second dose vaccine; This is a spontaneous report from a contactable consumer or other non-healthcare professional (patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number was not reported), via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient experienced nosebleed and was hesitating to take second dose vaccine. Reportedly, the patient stated that, the patient got the Pfizer vaccine (unspecified vaccine) 3 weeks ago, but the patient got a nosebleed an hour afterwards, so, the patient was kind of hesitating to take the second dose of the vaccine. The patient enquired if that was normal. Reporter seriousness for nosebleed, hesitating to take second dose vaccine was reported as unspecified. The outcome of the event was unknown.   No follow-up attempts are needed. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Epistaxis
Clinical narrative: nosebleed, hesitating to take second dose vaccine; This is a spontaneous report from a contactable consumer or other non-healthcare professional (patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number was not reported), via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient experienced nosebleed and was hesitating to take second dose vaccine. Reportedly, the patient stated that, the patient got the Pfizer vaccine (unspecified vaccine) 3 weeks ago, but the patient got a nosebleed an hour afterwards, so, the patient was kind of hesitating to take the second dose of the vaccine. The patient enquired if that was normal. Reporter seriousness for nosebleed, hesitating to take second dose vaccine was reported as unspecified. The outcome of the event was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Retching, Vertigo
Clinical narrative: Within 5 mins of vaccination -anaphylactic reaction including: extreme vertigo, facial flushing, nausea, tongue swelling and mouth tingling, respiratory distress. EMS was called but patient declined transport after speaking with her doctor. Patient given benedryl, rescue inhalers, nebulizers, and steroids .
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anaphylactic reaction, Flushing, Nausea, Paraesthesia oral, Respiratory distress
Clinical narrative: Within 5 mins of vaccination -anaphylactic reaction including: extreme vertigo, facial flushing, nausea, tongue swelling and mouth tingling, respiratory distress. EMS was called but patient declined transport after speaking with her doctor. Patient given benedryl, rescue inhalers, nebulizers, and steroids .
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Swollen tongue, Vertigo
Clinical narrative: Within 5 mins of vaccination -anaphylactic reaction including: extreme vertigo, facial flushing, nausea, tongue swelling and mouth tingling, respiratory distress. EMS was called but patient declined transport after speaking with her doctor. Patient given benedryl, rescue inhalers, nebulizers, and steroids .
Sex: U
Vaccine: HIBV
Symptoms: Product administered to patient of inappropriate age, Product label confusion, Wrong product administered
Clinical narrative: No additional adverse events; Wrong vaccine administered; Inappropriate age at vaccine administration; Product label confusion; This spontaneous case report has been received from a practice lead, referring to a 17 years-old patient of unknown gender. The patient's concurrent conditions, pertinent medical history, concomitant medications, drug and/or allergy reactions were provided.  On 30-SEP-2021, the patient was inadvertently vaccinated with haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) 0.5 milliliter administered intramuscularly (strength, vaccination scheme, anatomical location of administration, were not reported; ; lot # S023646 has been verified as valid lot number and expiration date reported and established as 31-MAR-2022)  for prophylaxis (wrong product administered, product administered to patient of inappropriate age).   The patient was supposed to received meningococcal vaccine b rfhbp/nada/nhba omv (BEXSERO) (strength, dose, vaccination scheme, route and anatomical location of administration, lot number and expiration date were not reported) for prophylaxis, The reporter confirmed the patient did not received meningococcal vaccine b rfhbp/nada/nhba omv (BEXSERO) and is scheduled to receive it at a later date. The customer reported since the products both had meningococcal on the box (product label confusion). No additional adverse event was reported. No further information was reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: Improper storage of product in use; No additional adverse events; This spontaneous report was received from a Register Nurse referring to a patient of unknown age and gender. The patient's medical history, concomitant medications, drug allergies, or reactions were not reported.   On 28-SEP-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) lot # T032932, that has been verified to be valid for varicella virus vaccine live (Oka/Merck) (VARIVAX) , expiration date reported as 28-SEP-2022, 1 dosage form for prophylaxis (strength and administration route were not provided) (product storage error).  The vaccine was exposed to a temperature above of less 3 Celsius degrees (C) for a time frame of 3 hours; the vaccine did not experience previous temperature excursions. No adverse events were reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: Improper storage of product in use; No additional adverse events; This spontaneous report was received from a Register Nurse referring to a patient of unknown age and gender. The patient's medical history, concomitant medications, drug allergies, or reactions were not reported.   On 26-AUG-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) lot # T032932, that has been verified to be valid for varicella virus vaccine live (Oka/Merck) (VARIVAX) , expiration date reported as 28-SEP-2022, 1 dosage form for prophylaxis (strength and administration route were not provided) (product storage error).  The vaccine was exposed to a temperature above of less 3 Celsius degrees (C) for a time frame of 3 hours; the vaccine did not experience previous temperature excursions. No adverse events were reported
Age: 23.0
Sex: F
Vaccine: HPV9
Symptoms: Incomplete course of vaccination, No adverse event
Clinical narrative: her first dose of Gardasil 9 approximately three years ago. What is the recommendation for series; No additional AE information reported; This spontaneous report was received from a nurse concerning a currently 26-year-old female patient. No concurrent condition, medical history, or concomitant therapy was reported.    In 2018 (reported as approximately 3 years ago), the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) (strength, dose, route, lot # and expiration date were unknown) for prophylaxis. The reporter requested the recommendation for series completion (inappropriate schedule of product administration). No adverse event was reported.
Age: 49.0
Sex: F
Vaccine: PPV
Symptoms: Asthma, Condition aggravated
Clinical narrative: asthma; This spontaneous report was received from a pharmacist, referring to a 55-year-old female patient. The patient's pertinent medical history included asthma and pneumonia. Information regarding the patient's drug reactions/allergies and concomitant medication was not provided.  In approximately 2015 (also reported as at the age of 49 years old), the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (dose, strength, route, lot# and expiration date were not provided) for prophylaxis.  On an unknown date, the patient experienced asthma. It was unknown if the asthma was diagnosed before or after pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23). The outcome of asthma was unknown.  The causality assessment between the event and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was not provided.
Sex: U
Vaccine: HEPA
Symptoms: No adverse event, Product storage error
Clinical narrative: she denied further AE; She reported that VAQTA was administered to a patiient after experiencing a temperature excursion; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided.      On 05-OCT-2021, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) lot # T013204, expiration date on 03-DEC-2021 (conflicting information also reported as 13-DEC-2021) 0.5 milliliter, for prophylaxis (strength, route of administration and anatomical location were not reported).   Vaccine was administered after experiencing a temperature excursion (product storage error); it was stored at 50.5°F during a time frame of 0 hours and 30 minutes. There was no previous temperature excursions and further Adverse Event (AE) were denied (no adverse event).  This one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2110USA007288: US-009507513-2110USA007310: US-009507513-2110USA007316: US-009507513-2110USA007379: US-009507513-2110USA007269: US-009507513-2110USA007007: US-009507513-2110USA007272: